MingSight Pharmaceuticals, Inc
3 clinical trials · Sponsor
◉ Watch MingSight Pharmaceuticals, Inc
| Record | Firm | Date |
|---|---|---|
| A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL (NCT06979076) | MingSight Pharmaceuticals, Inc | 2026-07-01 |
| A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma (NCT05720052) | MingSight Pharmaceuticals, Inc | 2023-02-06 |
| A Study Of The Selective PKC-β Inhibitor MS- 553 (NCT03492125) | MingSight Pharmaceuticals, Inc | 2018-05-25 |
Track MingSight Pharmaceuticals, Inc automatically
Every clearance here is in the API, with alerts when new ones post.